Cost-effectiveness Analysis of Recombinant Human Thrombopoietin Combined with Conventional Regimen in the Treatment of Sepsis-Associated Thrombocytopeni
- VernacularTitle:重组人血小板生成素联合常规方案治疗脓毒症相关血小板减少症的成本-效果分析
- Author:
Yuxin TANG
1
;
Tianyu GAN
;
Shuling WANG
Author Information
1. 沈阳药科大学工商管理学院 辽宁 沈阳 110016
- Keywords:
recombinant human thrombopoietin;
conventional treatment;
sepsis-associated thrombocytopenia;
meta-analysis;
minimum cost analysis;
cost-effectiveness analysis
- From:
Chinese Health Economics
2024;43(10):54-61
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the economy of recombinant human thrombopoietin(rhTPO)combined with conventional therapy compared with conventional therapy in the treatment of sepsis-associated thrombocytopenia(SIT)from the perspective of China's health service system.Methods:The decision tree model was constructed,and the minimum cost analysis and cost-effectiveness analysis were used to evaluate the economy based on the characteristics of sepsis.The economy was judged by two willingness to pay thresholds,and then the stability of the results was tested by sensitivity analysis.Results:rhTPO combined with conventional therapy can save 520.58 yuan for each 1%increase in survival rate compared with conventional therapy alone,which is an absolute advantage program.The single factor sensitivity analysis showed that the daily cost of ICU medical service and the duration of CRRT in the control group and the daily cost of ICU medical service in the experimental group had a great influence on the results,and the stability of the parameter outcome was good.The probability sensitivity analysis showed that when the willingness to pay threshold changes ranged 0~268 074 yuan,rhTPO has a 100%economical probability.Conclusion:Under the existing evidence,rhTPO combined with conventional treatment for SIT treatment is more economical on the basis of improving survival rate and equal safety.